Funding for this research was provided by:
Science and Technology Planning Project of Guangdong Province (2019B030316028)
National Natural Science Foundation of China (81702047, 81772191, 91842106 and 8181101118)
State Key Laboratory of Respiratory Disease (SKLRD-QN-201715, SKLRD-QN-201912 and SKLRD-Z-202007)
The National Key Research and Development Program of China (2018YFC1200100, 2018ZX10301403, 2018YFC1311900)
the emergency grants for prevention and control of SARS-CoV-2 of Ministry of Science and Technology (2020YFC0841400)
the emergency grants for prevention and control of SARS-CoV-2 of Guangdong province (2020B1111320003, 2020B111108001, 2018B020207013, 2020B111112003)
the Guangdong Province Basic and Applied Basic Research Fund (2020A1515010911)
Guangdong Provincial Key Laboratory of Genome Read and Write (2017B030301011)
Guangzhou Medical University High-level University Innovation Team Training Program ( No.159)
Received: 15 July 2020
Accepted: 5 February 2021
First Online: 22 February 2021
Ethics approval and consent to participate
: The overall research plan was reviewed and approved by the Ethics Committees of BGI-Shenzhen (No. BGI-IRB 20008), first affiliated hospital of Guangzhou Medical University, the fifth affiliated hospital of Sun Yat-sen University, and Yangjiang People’s hospital on the use of human samples for experimental studies. Written informed consent was obtained from all participants enrolled in the studies. All experiments were performed in accordance with relevant guidelines and regulations. The research conformed to the principles of the Helsinki Declaration.
: Informed consent was collected from all subjects to publish de-identified data.
: The authors declare no competing interests.